SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

05 Aug 2022 Evaluate
The sales for the June 2022 quarter moved down to Rs. 5929.00 millions as compared to Rs. 7491.70 millions during the year-ago period.Net profit was down at Rs. 325.50  millions against Rs. 1999.10 millions recorded in the corresponding quarter a year ago.The net profit spiraled down by -83.72%.A decline of 2098.70 millions was observed in the OP in the quarter ended June 2022 from 2979.80 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 5929.00 7491.70 -20.86 5929.00 7491.70 -20.86 26109.90 22385.50 16.64
Other Income 180.20 122.40 47.22 180.20 122.40 47.22 626.50 811.20 -22.77
PBIDT 2098.70 2979.80 -29.57 2098.70 2979.80 -29.57 8983.80 7932.40 13.25
Interest 36.40 22.50 61.78 36.40 22.50 61.78 104.90 151.10 -30.58
PBDT 699.00 2957.30 -76.36 699.00 2957.30 -76.36 8878.90 7781.30 14.11
Depreciation 265.10 270.00 -1.81 265.10 270.00 -1.81 1150.00 1094.10 5.11
PBT 433.90 2687.30 -83.85 433.90 2687.30 -83.85 7728.90 6687.20 15.58
TAX 108.40 688.20 -84.25 108.40 688.20 -84.25 1603.30 1711.10 -6.30
Deferred Tax -154.10 -19.70 682.23 -154.10 -19.70 682.23 -359.30 -125.20 186.98
PAT 325.50 1999.10 -83.72 325.50 1999.10 -83.72 6125.60 4976.10 23.10
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 35.40 39.77 -11.01 35.40 39.77 -11.01 34.41 35.44 -2.90

Pfizer Share Price

4849.80 -15.50 (-0.32%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×